Virum, Denmark

Mogens Winkel Madsen

USPTO Granted Patents = 3 

 

 

Average Co-Inventor Count = 2.9

ph-index = 2

Forward Citations = 16(Granted Patents)


Company Filing History:


Years Active: 2003-2021

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Mogens Winkel Madsen: Innovator in Medical Liposome Technology

Introduction

Mogens Winkel Madsen is a notable inventor based in Virum, Denmark. He has made significant contributions to the field of medical technology, particularly in the development of liposome-based therapies. With a total of 3 patents to his name, Madsen's work focuses on improving the efficacy and safety of therapeutic agents used in cancer treatment.

Latest Patents

Madsen's latest patents include innovative approaches to the medical use of sPLA2 hydrolysable liposomes. One of his key inventions relates to the targeted delivery of therapeutic agents to cancerous tissues, aiming to reduce side effects such as nephrotoxicity, neurotoxicity, and gastrointestinal toxicity. Another significant patent addresses the storage stability of sPLA2 hydrolysable liposomes, particularly when stored at temperatures between 2-8 degrees Celsius. This invention enhances the encapsulation of cisplatin, a common chemotherapeutic agent, thereby improving its effectiveness.

Career Highlights

Throughout his career, Madsen has worked with various companies, including Bio-bedst Aps and Leo Pharma A/S. His experience in these organizations has allowed him to refine his expertise in liposome technology and its applications in medicine.

Collaborations

Madsen has collaborated with notable professionals in his field, including Sune Allan Petersen and Anders Falk Vikbjerg. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Mogens Winkel Madsen is a distinguished inventor whose work in medical liposome technology has the potential to revolutionize cancer treatment. His innovative patents reflect a commitment to improving patient outcomes through targeted therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…